Evidence map›Paper›PMID 33851243›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2021

Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.

R Laudicella, N Quartuccio, G Argiroffi, P Alongi, L Baratto, E Califaretti, V Frantellizzi, G De Vincentis, A Del Sole, L Evangelista and 5 more

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Dual-tracer PET/CT with [European journal of nuclear medicine and molecular imaging · 2026
    Trial
  3. Advancements in nanotheranostics for glioma therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  4. Review
  5. Review
  6. [European journal of nuclear medicine and molecular imaging · 2023
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 3 countries.

R LaudicellaDepartment of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy.
N QuartuccioNuclear Medicine Unit, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Palermo, Italy.
G ArgiroffiDepartment of Health Sciences, University of Milan, Milan, Italy.
P AlongiNuclear Medicine Unit,, Fondazione Istituto G. Giglio, Ct. da Pietra Pollastra-pisciotto, Cefalù, Italy.
L BarattoDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA, USA.
E CalifarettiDivision of Nuclear Medicine, Department of Medical Sciences, University of Turin, Corso AM Dogliotti 14, 10126, Turin, Italy.
V FrantellizziDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza, "Sapienza" University of Rome, Rome, Italy.
G De VincentisDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza, "Sapienza" University of Rome, Rome, Italy.
A Del SoleDepartment of Health Sciences, University of Milan, Milan, Italy.
L EvangelistaNuclear Medicine Unit, Department of Medicine - DIMED, University of Padua, Padua, Italy.
S BaldariDepartment of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, Italy.
S BisdasDepartment of Neuroradiology, University College London, London, UK.
Francesco Ceci *Division of Nuclear Medicine, IEO European Institute of Oncology, IRCCS, Milan, Italy. francesco.ceci83@gmail.com.ORCID http://orcid.org/0000-0001-9785-5248
Andrei Iagaru *Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, CA, USA.
Young Italian Association of Nuclear Medicine (AIMN) group
Sapienza University of Rome · ITStanford University · USUniversity of Messina · ITUniversity of Milan · ITAzienda di Rilievo Nazionale ed Alta Specializzazione · ITFondazione Istituto G. Giglio di Cefalù · ITRipamonti · ITUniversity College London · GBUniversity of Padua · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective of this review was to explore the potential clinical application of unconventional non-amino acid PET radiopharmaceuticals in patients with gliomas.

methodsA comprehensive search strategy was used based on SCOPUS and PubMed databases using the following string: ("perfusion" OR "angiogenesis" OR "hypoxia" OR "neuroinflammation" OR proliferation OR invasiveness) AND ("brain tumor" OR "glioma") AND ("Positron Emission Tomography" OR PET). From all studies published in English, the most relevant articles were selected for this review, evaluating the mostly used PET radiopharmaceuticals in research centers, beyond amino acid radiotracers and 2-[

resultsAt present, the use of non-amino acid PET radiopharmaceuticals specifically designed to assess perfusion, angiogenesis, hypoxia, neuroinflammation, cell proliferation, tumor invasiveness, and other biological features in glioma is still limited.

conclusionThe use of investigational PET radiopharmaceuticals should be further explored considering their promising potential and studies specifically designed to validate these preliminary findings are needed. In the clinical scenario, advancements in the development of new PET radiopharmaceuticals and new imaging technologies (e.g., PET/MR and the application of the artificial intelligence to medical images) might contribute to improve the clinical translation of these novel radiotracers in the assessment of gliomas.

Indexed as

Brain NeoplasmsGliomaArtificial IntelligenceFluorodeoxyglucose F18HumansMolecular ImagingPositron-Emission TomographyRadiopharmaceuticalsTomography, X-Ray ComputedFluorodeoxyglucose F18RadiopharmaceuticalsAngiogenesisGliomaNeuroinflammationPerfusionPETProliferation

Identifiers

PMID33851243
OpenAlexW3154431519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.